Comment from Children's Tumor Foundation

Summary: The Children's Tumor Foundation (CTF) supports the FDA's drug repurposing initiative and recommends specific high-priority opportunities for treating neurofibromatosis. They advocate for regulatory facilitation to encourage pharmaceutical companies to pursue label expansions for drugs that show clinical benefit but lack commercial incentives for rare diseases.